Lv3
360 积分 2022-11-16 加入
Body Composition and Treatment Response in Heart Failure With Preserved Ejection Fraction
3天前
已完结
Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis
1个月前
已完结
Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes
1个月前
已完结
Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity
1个月前
已完结
Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5–15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials
3个月前
已完结
Tirzepatide for Obesity Treatment and Diabetes Prevention
3个月前
已完结
Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects
5个月前
已完结
Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment
5个月前
已完结
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
5个月前
已完结
The impact of nanobodies on GPCR structural biology and their potential as therapeutic agents
6个月前
已完结
皖公网安备34019202002308
